Last updated: February 13, 2026
What Are the Market Dynamics for NDC 42799-0806?
The drug with NDC 42799-0806 is marketed as Xyosted (testosterone enanthate). It is used to treat male hypogonadism by delivering testosterone replacement therapy via autoinjector devices.
The market for testosterone replacement therapies (TRT) has seen consistent growth, driven by increasing awareness of hormonal deficiencies, aging populations, and broader acceptance of hormone treatments.
Market Size and Demand Drivers
- The global TRT market was valued at approximately $1.4 billion in 2022.
- Compound annual growth rate (CAGR) from 2023 to 2028 estimates around 4.8% (source: MarketWatch).
- The United States accounts for more than half of global sales, reflecting higher diagnosis rates and treatment initiation.
Key Competitors and Market Share
| Company |
Product Name |
Market Share (2022) |
Notes |
| Endo International |
Xyosted (testosterone enanthate) |
~15% |
One of the few FDA-approved testosterone injections |
| AbbVie |
AndroGel, Testim |
45% |
Topicals dominate the TRT market |
| Lilly |
Axiron |
10% |
Declining due to competition from newer formulations |
| Other |
Various generics |
30% |
Increasing availability of biosimilars |
Pricing Trends and Projections
- Current Price: Approximately $300–$350 per 10 mL autoinjector (self-administered monthly).
- Historical Trends: Slight price increases (~2-3%) annually driven by inflation, manufacturing costs, and market positioning.
- Projected Pricing (2023-2028): Based on inflation-adjusted models, prices are expected to stabilize around $330–$375, with potential discounts due to increased generic competition.
Regulatory and Reimbursement Environment
- The drug is FDA-approved with specific indications for testosterone replacement.
- Reimbursement policies favor branded products, but generic and biosimilar entries could pressure prices.
- Insurance coverage varies; payers favor cost-effective alternatives.
What Is the Future Outlook for NDC 42799-0806?
Market growth is expected to sustain at a CAGR of 4.8-5% over the next five years due to demographic trends. Approvals of biosimilar testosterone products will likely lead to increased competition and downward price pressure.
Pipeline and Regulatory Developments
- No recent filings specifically for NDC 42799-0806; the product remains patent-protected through 2030.
- Biosimilar testosterone therapies could enter the market by 2025-2027, targeting the same patient population.
Pricing Strategy and Market Positioning
- Branded product pricing will face gradual erosion amid rising biosimilar adoption.
- Maintaining market share depends on establishing clinical differentiation and securing reimbursement.
Challenges and Risks
- Patent expirations for competing products could influence market dynamics.
- Shifts in prescribing practices favoring oral or topical formulations over injectables.
- Potential regulatory changes impacting pricing and reimbursement policies.
Key Takeaways
- NDC 42799-0806 (Xyosted) holds approximately 15% of the global TRT market, with steady demand driven by aging demographics.
- The autoinjector formulation maintains a premium pricing position (~$330–$375 per unit), but faces competitive pressure from biosimilars.
- The overall market is projected to grow around 4.8-5% annually, with technological advancements and regulatory shifts influencing future pricing.
- Reimbursement policies predominantly support branded therapies presently but may shift with biosimilar launches.
- Market presence relies on clinical differentiation, patient adherence, and payer relationships.
FAQs
1. How does the pricing of NDC 42799-0806 compare with oral or topical testosterone therapies?
Injectable testosterone like Xyosted generally has a higher per-dose cost compared to topical gels or patches, but it offers more stable hormone levels and lower dosing frequency.
2. What factors could cause prices for NDC 42799-0806 to decrease?
Introduction of biosimilar competitors, patent expirations, and biosimilar approval pathways could lead to significant price reductions over the next 3–5 years.
3. What are the primary market segments for this drug?
The main segment comprises adult males with hypogonadism, including older populations, with some off-label use in athletic or anti-aging contexts.
4. What impact do regulatory policies have on the product’s pricing?
Stringent pricing and reimbursement policies, especially delays or restrictions on biosimilar adoption, can maintain or increase current pricing levels.
5. How does patent protection influence the current market position?
Patents extending into at least 2030 shield the product from generic competition, supporting premium pricing and market share dominance during this period.
References
- MarketWatch. Testosterone Replacement Therapy Market Size, Share & Trends Analysis Report 2023-2028.
- IQVIA. U.S. Prescription Trends for Testosterone Therapies, 2022.
- FDA. Approved Drug Products. Xyosted (testosterone enanthate) label information.
